Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials.
Saved in:
| Title: | Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials. |
|---|---|
| Authors: | Kinnunen KM; IXICO, London, United Kingdom., Mullin AP; Critical Path Institute, Tucson, AZ, United States.; Wave Life Sciences, Ltd., Cambridge, MA, United States., Pustina D; CHDI Management/CHDI Foundation, Princeton, NJ, United States., Turner EC; Critical Path Institute, Tucson, AZ, United States., Burton J; Critical Path Institute, Tucson, AZ, United States., Gordon MF; Teva Pharmaceuticals, West Chester, PA, United States., Scahill RI; Huntington's Disease Research Centre, UCL Institute of Neurology, London, United Kingdom., Gantman EC; CHDI Management/CHDI Foundation, Princeton, NJ, United States., Noble S; CHDI Management/CHDI Foundation, Princeton, NJ, United States., Romero K; Critical Path Institute, Tucson, AZ, United States., Georgiou-Karistianis N; School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia., Schwarz AJ; Takeda Pharmaceuticals, Ltd., Cambridge, MA, United States. |
| Source: | Frontiers in neurology [Front Neurol] 2021 Oct 22; Vol. 12, pp. 712565. Date of Electronic Publication: 2021 Oct 22 (Print Publication: 2021). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101546899 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2295 (Print) Linking ISSN: 16642295 NLM ISO Abbreviation: Front Neurol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
